B³ Pharma is a late-stage private biopharma company specializing in Peptide-Drug Conjugates (PDC) with its innovative Angiopep technology. Lead candidate ANG1005 has shown effective blood-brain barrier penetration and received Orphan Drug Designation in the U.S. The company is preparing a pivotal Phase III trial in 2026, supported by strong patent protection through 2036.
At the forefront of biotechnology, B³ Pharma is advancing its Angiopep platform to address one of the toughest challenges in oncology: delivering therapies across the blood-brain barrier. With promising clinical results and regulatory support, the company is shaping the future of treatment for patients with brain metastases and leptomeningeal carcinomatosis.
B³ Pharma is guided by a team of seasoned executives with deep expertise in biotechnology, venture capital, and clinical development. Their combined vision and track record in building successful companies are key assets in advancing the company’s mission to bring breakthrough treatments to patients.
